Human Insulin NPH and Insulin Aspart in Type 1 Diabetes

• Status: Completed
• Trial end date: 2002-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in South America. This aim of this trial is to evaluate the comparative prandial blood glucose lowering profile in subjects with type 1 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting; Isophane insulin, beef; Isophane Insulin, Human

Criteria

Inclusion Criteria:

• Type 1 diabetes for at least 12 months

• Treatment with insulin NPH

• Body Mass Index (BMI) below 30 kg/m2

Exclusion Criteria:

• Total daily insulin dose greater than 1.40 IU/kg

• Treatment with oral antidiabetic drugs (OADs)